Vivaldi Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Vivaldi Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,913	Closed	-$256K	–	228
2024 Q2	$256K	Sell	10,913 -460	-4%	-$11.6K	0.07%	183
2024 Q1	$283K	Buy	+11,373	New	+$342K	0.08%	174
2023 Q4	–	Sell	-7,740	Closed	-$216K	–	221
2023 Q3	$216K	Buy	7,740 +911	+13%	+$29.8K	0.07%	174
2023 Q2	$233K	Hold	6,829	–	–	0.07%	172
2023 Q1	$205K	Hold	6,829	–	–	0.06%	185
2022 Q4	$206K	Sell	6,829 -47	-0.7%	-$1.49K	0.05%	227
2022 Q3	$226K	Sell	6,876 -295	-4%	-$10.8K	0.06%	193
2022 Q2	$226K	Hold	7,171	–	–	0.06%	191
2022 Q1	$232K	Sell	7,171 -126	-2%	-$6.01K	0.06%	187
2021 Q4	$447K	Sell	7,297 -17	-0.2%	-$1.18K	0.1%	130
2021 Q3	$547K	Sell	7,314 -117	-2%	-$9.82K	0.12%	121
2021 Q2	$611K	Sell	7,431 -41	-0.5%	-$3.49K	0.12%	123
2021 Q1	$572K	Buy	+7,472	New	+$741K	0.11%	130

Other funds holding ARKG

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Vivaldi Capital Management's ARKG Position: Q3 2024 in Review

Vivaldi Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 10,913 shares — an estimated $256K sold.

Vivaldi Capital Management first reported a position in ARKG in Q1 2021 and held it in 13 quarters. The position peaked at $611K in Q2 2021. 238 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

Vivaldi Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
Vivaldi Capital Management sold 10,913 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $256K.
Vivaldi Capital Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 13 quarters.
Vivaldi Capital Management's ARK Genomic Revolution ETF position peaked at $611K in Q2 2021.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Vivaldi Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.